TCRT Valuation

Alaunos Therapeutics Inc

Add to Watchlist

Advanced Chart

2.990

-0.11(-3.548%)1D

Overview
Forecast
Valuation
Earnings

TCRT Relative Valuation

TCRT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TCRT is overvalued; if below, it's undervalued.

Historical Valuation

Alaunos Therapeutics Inc (TCRT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.13. The fair price of Alaunos Therapeutics Inc (TCRT) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：2.99

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

5.66

P/B

Median3y

4.31

Median5y

4.47

-48.35

FCF Yield

Median3y

-114.92

Median5y

-72.60

Competitors Valuation Multiple

The average P/S ratio for TCRT's competitors is 2.08, providing a benchmark for relative valuation. Alaunos Therapeutics Inc Corp (TCRT) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 100.00%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TCRT.O

Alaunos Therapeutics Inc

Loss

Average P/S: 2.08

100.00%